Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023.
Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET).
Full details for the conference call and webcast are as follows:
| Date | March 29, 2023 |
| Time | 3:00 p.m. CET (9 a.m. ET) |
| U.S. Dial-in Number: | +1 877-451-6152 |
| Int’l Dial-in Number: | +1 201-389-0879 |
| Conference ID: | 13736670 |
| Webcast: | Join the live webcast here or at https://www.medigene.com/investors-media/reports-presentations |
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: https://www.medigene.com/investors-media/reports-presentations
--- end of press release ---
About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
Contacts
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
